Protein-Based Cancer Therapeutics Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 14.56 Billion |
| Market Size (2030) | USD 34.47 Billion |
| CAGR (2025 - 2030) | 18.82% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Protein-Based Cancer Therapeutics Market Analysis
The Protein-Based Cancer Therapeutics Market size is estimated at USD 14.56 billion in 2025, and is expected to reach USD 34.47 billion by 2030, at a CAGR of 18.82% during the forecast period (2025-2030).
Major factors propelling the growth of the protein-based cancer therapeutics market are the increasing burden of cancer, technological advancements in protein engineering, and increasing investments in cancer research.
The increasing number of cancer patients is a crucial driving factor for the protein-based cancer therapeutics market. For instance, according to the American Cancer Society, in January 2024, it is estimated that the total number of new cancer cases will ramp up from 1.9 million in 2023 to 2.0 million in 2024. The most common type of cancers diagnosed in 2023 were breast, lung, and hematological malignancies in the United States. The escalating incidence of cancer intensifies the demand for innovative therapeutic solutions, driving advancements in protein-based therapies that target specific cancer pathways and enhance treatment efficacy.
Similarly, according to a report published by Revue du praticien in January 2024, the incidence of cancer in metropolitan France is rising, with 433,136 new cases in 2023. The increasing incidence of cancer in metropolitan France drives the growth of the protein-based cancer therapeutics market by necessitating innovative and targeted treatment approaches such as sprycel and sutent that leverage protein-based mechanisms to enhance therapeutic efficacy and improve patient outcomes.
Moreover, the continuous advancements in biotechnology and genetic engineering have led to the development of innovative protein-based cancer therapeutics. These technologies have created more targeted and effective treatments, such as monoclonal antibodies and antibody-drug conjugates. For instance, in July 2023, C4 Therapeutics, Inc. (C4T) received clearance from the United States Food and Drug Administration (FDA) for its investigational new drug (IND) application for CFT8919, a potent and selective orally bioavailable BiDAC degrader targeting EGFR L858R in non-small cell lung cancer (NSCLC) patients. This development underscores the ongoing advancement of innovative therapies in oncology, contributing to the evolving landscape of the protein-based cancer therapeutics market.
Similarly, the rising investments in the research and development activities in the protein-based cancer therapeutics market are expected to boost the market's growth during the forecast period. For instance, in October 2023, the Australian Centre for Targeted Therapeutics (ACTT) was launched with USD 15 million in funding from the Medical Research Future Fund to develop targeted protein degrader medicines and technology for cancer treatment. This collaboration, involving leading research institutions, aims to address neuroblastoma and prostate cancer through innovative therapies. The initiative is poised to drive advancements in the protein-based cancer therapeutics market by fostering novel treatment approaches that target previously untreatable disease-causing proteins.
In conclusion, the growth of the protein-based cancer therapeutics market is propelled by the rising incidence of cancer, advancements in biotechnology, and increasing investments, all of which drive the development of innovative and targeted therapeutic solutions. However, the high development costs, stringent regulatory norms, and potential for drug resistance are restraining the growth of the protein-based cancer therapeutics market.
Protein-Based Cancer Therapeutics Market Trends
Breast Cancer Segment is Expected to Witness a Significant Growth Over the Forecast Period
Breast cancer is one of the most prevalent cancer cases, and the emergence of protein-based cancer therapeutics transformed the treatment landscape. These advanced therapies offer enhanced safety and efficacy, significantly improving patient quality of life.
Recent advancements in molecular biology have deepened the understanding of the genetic and molecular mechanisms involved in breast cancer development. This progress has paved the way for targeted protein-based therapies, which focus on specific proteins and pathways driving tumor growth and progression. In October 2024, the FDA granted approval for inavolisib in combination with palbociclib and fulvestrant for treating adults with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative advanced or metastatic breast cancer, specifically following recurrence post-adjuvant endocrine therapy. Additionally, the FoundationOne Liquid CDx assay was approved as a companion diagnostic to identify suitable patients for this treatment regimen. This development highlights the innovation in addressing complex cancer types, contributing to advancements within the breast cancer segment.
Protein-based therapies, including monoclonal antibodies, small molecule inhibitors, and antibody-drug conjugates, provide a more precise treatment method than conventional therapies. By selectively targeting cancer cells while sparing healthy tissues, these therapies reduce side effects and lead to better patient outcomes. For instance, in January 2023, AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) received European Union approval as a monotherapy for adult patients with unresectable or metastatic HER2-low breast cancer who have undergone prior chemotherapy. This development highlights significant advancements in targeted therapies within the breast cancer segment of the protein-based cancer therapeutics market.
Similarly, according to a report published in the Frontiers in Pharmacology in January 2023, the advancements in precision medicine and the increasing understanding of cancer biology drive the development of targeted protein-based therapeutics, enabling more effective treatment options for patients. Additionally, the growing focus on personalized medicine fosters the innovation of novel biomolecules and biologics tailored to individual patient profiles. These factors are significantly propelling the growth of the protein-based cancer therapeutics market by enhancing treatment efficacy and patient outcomes.
In conclusion, integrating innovative protein-based cancer therapeutics and advancements in molecular biology and precision medicine transforms breast cancer treatment, significantly improves efficacy and safety, and propels the breast cancer segment's growth.
North America is Expected to Hold a Significant Share in the Market Over the Forecast Period
Significant drivers of protein-based cancer therapeutics market growth in North America include the region's substantial demand for novel cancer treatment methods and the increasing prevalence of cancer, which collectively account for a significant market share.
For instance, according to the American Cancer Society in December 2023, the prevalence of lung cancer is increasing in the country. The United States reported 238,340 new lung cancer cases in 2023 compared to 236,740 in 2022. This shows a rapid increase in the incidence of cancer cases in the country. Over the forecast period, the incidence of cancer will further increase, raising the demand for cancer treatments and propelling the growth of the protein-based cancer therapeutics market.
Similarly, according to the Canadian Cancer Society's 2023 report, cancer represents a significant healthcare burden in Canada, with its incidence rising. The report highlighted that in 2023, 124,200 men and 114,900 women were diagnosed with cancer.
In addition, as per the same source, lung and bronchus cancer, breast cancer, prostate cancer, and colorectal cancer were the top four cancers that accounted for 46% of cancer diagnoses in the country in 2023. The rising prevalence of cancer indicates an increasing patient population that necessitates innovative and effective treatment options, thereby propelling growth in the demand for protein-based cancer therapeutics as healthcare providers seek targeted therapies to improve patient outcomes.
Moreover, the increasing growth strategies by key players in the region are expected to propel the growth of the protein-based cancer therapeutics market. For instance, in May 2024, Lantern Pharma Inc. entered into a strategic collaboration with Oregon Therapeutics to enhance the development of its innovative protein disulfide isomerase (PDI) inhibitor drug candidate, XCE853, for novel and targeted cancer indications. This partnership is poised to advance the therapeutic landscape, particularly in the protein-based cancer therapeutics market, as it leverages cutting-edge approaches to address unmet clinical needs.
In conclusion, the protein-based cancer therapeutics market's growth in North America is driven by rising cancer prevalence, demand for targeted treatment options, and strategic collaborations advancing innovative cancer therapies.
Protein-Based Cancer Therapeutics Industry Overview
Key players dominate the competitive landscape of the protein-based cancer therapeutics market. Companies are poised to leverage technological advancements and product innovations as new avenues for competition. Notable players in this arena encompass Abbott, AstraZeneca Plc, GlaxoSmithKline Plc, Johnson & Johnson Services, Inc., and Pfizer Inc., among others.
Protein-Based Cancer Therapeutics Market Leaders
-
Abbott
-
Astrazeneca PLC
-
GlaxoSmithKline PLC
-
Johnson & Johnson Services, Inc.
-
Pfizer, Inc.
- *Disclaimer: Major Players sorted in no particular order
Protein-Based Cancer Therapeutics Market News
- August 2024: The FDA granted accelerated approval for Adaptimmune, LLC's afamitresgene autoleucel, a genetically modified autologous T cell therapy targeting melanoma-associated antigen A4 (MAGE-A4). This approval applies to adult patients with unresectable or metastatic synovial sarcoma who have previously undergone chemotherapy.
- February 2024: BioNTech SE and Autolus Therapeutics plc formed a strategic collaboration to enhance their autologous CAR-T programs. The goal of commercialization is contingent upon regulatory approvals. This partnership included a license and option agreement and a securities purchase agreement.
Protein-Based Cancer Therapeutics Industry Segmentation
As per the report's scope, protein-based cancer therapeutics use biologically engineered proteins, such as monoclonal antibodies, fusion proteins, and hormones, to target specific cancer cells and pathways. These therapies aim to enhance treatment precision, improve patient outcomes, and reduce the side effects typically associated with traditional cancer treatments. The protein-based cancer therapeutics market is segmented by product type, application, end-user, and geography. The product type segment is divided into monoclonal antibodies, hormones, fusion proteins, and others. The others segment includes cytokines and therapeutic enzymes, among others. The application segment is further segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, and other cancer types. The end-user segment includes hospitals, ambulatory surgical centers, and others. The geography segment is further divided into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (in USD) for the above segments.
| By Product Type | Monoclonal Antibodies | ||
| Hormones | |||
| Fusion Proteins | |||
| Others | |||
| By Application | Breast Cancer | ||
| Lung Cancer | |||
| Colorectal Cancer | |||
| Prostate Cancer | |||
| Other Cancer Types | |||
| By End User | Hospitals | ||
| Ambulatory Surgical Centers | |||
| Other End Users | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle-East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Monoclonal Antibodies |
| Hormones |
| Fusion Proteins |
| Others |
| Breast Cancer |
| Lung Cancer |
| Colorectal Cancer |
| Prostate Cancer |
| Other Cancer Types |
| Hospitals |
| Ambulatory Surgical Centers |
| Other End Users |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle-East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Protein-Based Cancer Therapeutics Market Research Faqs
How big is the Protein-Based Cancer Therapeutics Market?
The Protein-Based Cancer Therapeutics Market size is expected to reach USD 14.56 billion in 2025 and grow at a CAGR of 18.82% to reach USD 34.47 billion by 2030.
What is the current Protein-Based Cancer Therapeutics Market size?
In 2025, the Protein-Based Cancer Therapeutics Market size is expected to reach USD 14.56 billion.
Who are the key players in Protein-Based Cancer Therapeutics Market?
Abbott, Astrazeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc. and Pfizer, Inc. are the major companies operating in the Protein-Based Cancer Therapeutics Market.
Which is the fastest growing region in Protein-Based Cancer Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Protein-Based Cancer Therapeutics Market?
In 2025, the North America accounts for the largest market share in Protein-Based Cancer Therapeutics Market.
What years does this Protein-Based Cancer Therapeutics Market cover, and what was the market size in 2024?
In 2024, the Protein-Based Cancer Therapeutics Market size was estimated at USD 11.82 billion. The report covers the Protein-Based Cancer Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Protein-Based Cancer Therapeutics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Protein-Based Cancer Therapeutics Industry Report
Statistics for the 2025 Protein-Based Cancer Therapeutics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Protein-Based Cancer Therapeutics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
